Spectral AI second quarter 2026 R&D revenue fell to $3.5M while FDA clearance enables commercial launch

Spectral AI reported a decline in research and development revenue for the second quarter of 2026 as the company transitioned from core development activities toward commercialization following May 2026 FDA clearance of its DeepView System. While revenue declined due to cost-sharing provisions in government contracts, the company improved its net loss position and maintained its full-year guidance.

Key Highlights

• The company received FDA De Novo clearance for the DeepView System for burn indication in May 2026, authorizing commercial distribution in the United States by year-end.
• Research and development revenue decreased to $3.5 million from $5.1 million in the prior year, driven by a narrower scope of reimbursed work and cost-share provisions in the BARDA Project BioShield contract.
• Cash and equivalents stood at $14.0 million as of June 30, 2026, supported by a $6.5 million draw on a credit facility with Avenue Capital Group following regulatory milestones.